Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1996 1
1998 1
1999 1
2001 2
2003 1
2007 1
2008 2
2009 2
2010 1
2012 2
2013 1
2015 1
2017 1
2021 1
2022 1
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
MiRNAs in renal cell carcinoma.
Miranda-Poma J, Trilla-Fuertes L, López-Camacho E, Zapater-Moros A, López-Vacas R, Lumbreras-Herrera MI, Pertejo-Fernandez A, Fresno-Vara JÁ, Espinosa-Arranz E, Gámez-Pozo A, Pinto-Marín Á. Miranda-Poma J, et al. Among authors: espinosa arranz e. Clin Transl Oncol. 2022 Nov;24(11):2055-2063. doi: 10.1007/s12094-022-02866-z. Epub 2022 Jun 21. Clin Transl Oncol. 2022. PMID: 35729452 Review.
SEOM-GEM clinical guidelines for cutaneous melanoma (2023).
Márquez-Rodas I, Muñoz Couselo E, Rodríguez Moreno JF, Arance Fernández AM, Berciano Guerrero MÁ, Campos Balea B, de la Cruz Merino L, Espinosa Arranz E, García Castaño A, Berrocal Jaime A. Márquez-Rodas I, et al. Among authors: espinosa arranz e. Clin Transl Oncol. 2024 Nov;26(11):2841-2855. doi: 10.1007/s12094-024-03497-2. Epub 2024 May 15. Clin Transl Oncol. 2024. PMID: 38748192 Free PMC article.
mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M. Pinto Marín A, et al. Among authors: espinosa arranz e. Urol Oncol. 2012 Jul-Aug;30(4):356-61. doi: 10.1016/j.urolonc.2009.11.008. Epub 2010 Mar 5. Urol Oncol. 2012. PMID: 20207176 Review.
Oxycodone: a pharmacological and clinical review.
Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Ordóñez Gallego A, et al. Among authors: espinosa arranz e. Clin Transl Oncol. 2007 May;9(5):298-307. doi: 10.1007/s12094-007-0057-9. Clin Transl Oncol. 2007. PMID: 17525040 Review.
[Perverted authorship].
Ordóñez Gallego A, Espinosa Arranz E. Ordóñez Gallego A, et al. Among authors: espinosa arranz e. Med Clin (Barc). 1998 Apr 25;110(14):548-9. Med Clin (Barc). 1998. PMID: 9646271 Spanish. No abstract available.
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
García Trevijano Cabetas M, Escario-Gómez M, González-Del Valle L, Sobrino Jiménez C, Bilbao Gomez-Martino C, Romero-Garrido JA, Benedi-González J, Espinosa Arranz E, Díaz Almirón M, Herrero Ambrosio A. García Trevijano Cabetas M, et al. Among authors: espinosa arranz e. Eur J Hosp Pharm. 2023 Sep;30(5):268-272. doi: 10.1136/ejhpharm-2021-002798. Epub 2021 Oct 7. Eur J Hosp Pharm. 2023. PMID: 34620687 Free PMC article.
Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast.
Álvarez Criado J, Zamora Auñon P, Martínez Marín V, GarcíaTrevijano Cabetas M, Collada Sánchez VL, Espinosa Arranz E, Romero-Garrido JA, Benedi-González J, Díaz Almirón M, Herrero Ambrosio A. Álvarez Criado J, et al. Among authors: espinosa arranz e. J Oncol Pharm Pract. 2024 Aug 2:10781552241269677. doi: 10.1177/10781552241269677. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 39095042
Eicosapentaenoic acid as a targeted therapy for cancer cachexia.
Belda-Iniesta C, de Castro Carpeno J, Fresno Vara JA, Cejas Guerrero P, Casado Saenz E, Espinosa Arranz E, Redondo Sanchez A, Feliu Battle J, Gonzalez Baron M. Belda-Iniesta C, et al. Among authors: espinosa arranz e. J Clin Oncol. 2003 Dec 15;21(24):4657-8; author reply 4658. doi: 10.1200/JCO.2003.99.154. J Clin Oncol. 2003. PMID: 14673061 No abstract available.
25 results